Search clinical trials for: BIBR 1048

Total 647 results

Boehringer Ingelheim

Completed

Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males

Healthy
Boehringer Ingelheim

Completed

Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Boehringer Ingelheim

Completed

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism

Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Italy, Netherlands, Norway, South Africa, Sweden
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

BIBR 953 ZW in Healthy Elderly Subjects

Healthy
Boehringer Ingelheim

Completed

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Neoplasms

United States
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

Colorectal Neoplasms

France
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

Healthy
Hartford Hospital
Merck Sharp & Dohme LLC

Completed

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Diabetes | Healthy Volunteers | Wound Infection

United States
Forest Laboratories

Completed

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Active, not recruiting

Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC (OPBC-02PREPEC)

Breast Reconstruction | Implant-Based Breast Reconstruction (IBBR)

Austria, Sweden, Germany, Hungary, Switzerland, United States, Italy
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Healthy
Israel Institute for Biological Research (IIBR)

Completed

Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Covid19

Israel
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Influenza

United States
Boehringer Ingelheim

Terminated

Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection

Lung Neoplasms
European Organisation for Research and Treatment...

Suspended

BIBX 1382 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

Healthy
Forest Laboratories

Completed

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Chronic Pancreatitis | Exocrine Pancreatic Insufficiency

United States, Italy, Ukraine
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Healthy
Jiong Wu
The First Affiliated Hospital with Nanjing Medical University; Second Affiliated... and other collaborators

Recruiting

Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA) (IBBR)

Breast Cancer

China

3

Subscribe